



SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company" or the "Group")

Appointment of Interim CFO

24 August 2026 - SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, has appointed Anita Slater as Interim CFO (non-Board) for an initial six-month term. Ms Slater will start her duties with immediate effect to ensure an orderly handover with an interim finance team.

Anita Slater has 30 years' experience in commercial and financial senior leadership roles including Board positions, and has worked across start-ups, AIM-listed firms, and FTSE top 10 companies in energy, infrastructure, and manufacturing. She started her career at BG Group (now Shell) where she worked for c.19 years and rose to be Portfolio & Planning Manager for the Global Business Development team and finished her term there as the Shell-BG Merger Exploration Transition Team Manager, following Shell's acquisition. Having left the oil and gas sector in 2016, Anita worked in the renewable energy and technology sectors and was focused on formulating and delivering growth strategies. She worked in executive (including CFO) roles with a number of companies in this space, including, Tokamak Energy, AIM-listed AMTE Power plc, mining and renewable energy ventures Blue International Group and Joule Africa.

She qualified as a Chartered Accountant at PwC and is a fellow of the Institute of Chartered Accountants in England and Wales (ICAEW) and is a Business & Finance Professional (BFP). She has a BSc (Hons) in Applied Economics from the University of Plymouth.

Alyson Levett, Interim Chair of SkinBioTherapeutics, said:

"On behalf of the Board, I am delighted to welcome Anita to SkinBio as interim CFO. She brings extensive experience in financial and commercial leadership, together with strong expertise in governance, risk and financial controls. We have made significant progress in strengthening the Group's governance and financial framework, and Anita's experience will be invaluable as we build on that work and the ongoing focus on the commercial development of the business."

The Company is in advanced discussions with potential NED candidates and looks forward to updating the market in due course, and is also intending to issue a business update by mid-September which will include further Board updates.

-Ends-

Thumbnail image



Interim CFO, Anita Slater

Full image available upon request

For more information please contact:

SkinBioTherapeutics plc
Alyson Levett, Interim Chair
Rachel Parsonage, Interim CFO

ir@skinbiotix.com

Singer Capital Markets (Nominated Adviser & Broker)

Alex Bond
Sara Hale
Patrick Weaver

+44 (0) 020 7496 3000

Vigo Consulting

Melanie Toyne-Sewell
Rozi Morris

+44 (0) 20 7390 0230
SkinBio@vigoconsulting.com

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life sciences company focused on skin health. The Group's proprietary platform technology, SkinBiotix[®], is based upon discoveries made by the translational dermatology team at the University of Manchester.

The Company's strategic approach to skin health is via two routes - tackling skin issues from the 'outside in' and the 'inside out'. The 'outside in' approach is represented by topical creams, and from the 'inside out', via oral supplement solutions which impact the skin via different axes such as the gut and the brain.

SkinBio's products and services are developed through evidence-based science and commercially focused innovation with the aim of supporting skin health, well-being, repair and beauty. SkinBio also has a contract manufacturing and distribution arm related to skin health and other healthcare products.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.SkinBioTherapeutics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOADXLFLQVLLBBV